“The survival rate comparison of non small cell lung carcinoma patients who are given by epidermal growth factor receptor-tyrosin kinase inhibitor and those given by first-line chemotherapy treatment”, NMSJ, vol. 6, no. 2, pp. 103–115, Jan. 2022, doi: 10.20956/nmsj.v6i2.18857.